Abstract
The SARS-CoV-2 infections are still imposing a great public health challenge despite the recent developments in vaccines and therapy. Searching for diagnostic and prognostic methods that are fast, low-cost and accurate is essential for disease control and patient recovery. The MALDI-TOF mass spectrometry technique is rapid, low cost and accurate when compared to other MS methods, thus its use is already reported in the literature for various applications, including microorganism identification, diagnosis and prognosis of diseases. Here we developed a prognostic method for COVID-19 using the proteomic profile of saliva samples submitted to MALDI-TOF and machine learning algorithms to train models for COVID-19 severity assessment. We achieved an accuracy of 88.5%, specificity of 85% and sensitivity of 91.5% for classification between mild/moderate and severe conditions. Then, we tested the model performance in an independent dataset, we achieved an accuracy, sensitivity and specificity of 67.18, 52.17 and 75.60% respectively. Saliva is already reported to have high inter-sample variation; however, our results demonstrates that this approach has the potential to be a prognostic method for COVID-19. Additionally, the technology used is already available in several clinics, facilitating the implementation of the method. Further investigation using a bigger dataset is necessary to consolidate the technique.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), GP (2018/18257-1, 2018/15549-1, 2020/04923-0), CW (2015/26722-8, 2017/03966-4), CRFM (2018/20468-0), PHB (2021/07490-0), ELD (2020/06409-1) and by Pro-Reitoria de Pesquisa da Universidade de Sao Paulo, PHB (2021.1.10424.1.9). GP (307854/2018-3), CW, and CRFM (302917/2019-5) were supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). The funders had no role in study design. L Rosa-Fernandes, LC Lazari, RM Zerbinati and VF Santiago were supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). M Palmieri was supported by Pro-Reitoria de Pesquisa da Universidade de Sao Paulo (2021.1.10424.1.9).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by Research Ethics Committee of the Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil, protocol number CAAE 35589320.6.0000.0061. The invited volunteers were informed about the objectives, propositions and conditions of this project, in which those who agreed to participate in the research signed the free and informed consent term. Demographics, clinical data and samples were collected uniquely after the understanding of the study protocol and consent acknowledgement by the participants. A questionnaire on the health status of each participant was carried out. All participant information and samples were anonymized before use.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon request to the authors.